BIAF has been in the news 409% more than usual
Sep 29, 2025, 10:33 PM
-32.38%
What does BIAF do
bioAffinity Technologies, based in San Antonio, Texas, focuses on non-invasive early-stage cancer diagnosis and treatment, employing 75 staff since its IPO on August 26, 2022. Its first product, CyPath Lung, aids in detecting early-stage lung cancer, enhancing patient intervention decisions.
BIAF has been in the news recently: bioAffinity Technologies, Inc. is currently undergoing a public offering led by WallachBeth Capital LLC, with plans to sell 1,921,799 shares at $2.50 each to generate significant gross proceeds. Additionally, bioAffinity Technologies has reported a 20% increase in revenue in the last quarter, fueled by strong sales and a growing customer base.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.